JP6594862B2 - 五員複素環縮合ピリジン系化合物、並びにその調製方法および用途 - Google Patents

五員複素環縮合ピリジン系化合物、並びにその調製方法および用途 Download PDF

Info

Publication number
JP6594862B2
JP6594862B2 JP2016520243A JP2016520243A JP6594862B2 JP 6594862 B2 JP6594862 B2 JP 6594862B2 JP 2016520243 A JP2016520243 A JP 2016520243A JP 2016520243 A JP2016520243 A JP 2016520243A JP 6594862 B2 JP6594862 B2 JP 6594862B2
Authority
JP
Japan
Prior art keywords
group
substituted
unsubstituted
pyridine
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016520243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521757A (ja
Inventor
競 康 沈
美 玉 耿
健 丁
兵 熊
▲ジン▼ 艾
宇 馳 馬
▲シン▼ 王
霞 彭
越 磊 陳
丹 ▲チー▼ 陳
韜 孟
蘭 萍 馬
寅 淳 季
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Haihe Pharmaceutical Co Ltd
Original Assignee
Shanghai Haihe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haihe Pharmaceutical Co Ltd filed Critical Shanghai Haihe Pharmaceutical Co Ltd
Publication of JP2016521757A publication Critical patent/JP2016521757A/ja
Application granted granted Critical
Publication of JP6594862B2 publication Critical patent/JP6594862B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016520243A 2013-06-19 2014-06-18 五員複素環縮合ピリジン系化合物、並びにその調製方法および用途 Active JP6594862B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310245354.8 2013-06-19
CN201310245354.8A CN104230922B (zh) 2013-06-19 2013-06-19 一类五元杂环并吡啶类化合物及其制备方法和用途
PCT/CN2014/000600 WO2014201857A1 (zh) 2013-06-19 2014-06-18 一类五元杂环并吡啶类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
JP2016521757A JP2016521757A (ja) 2016-07-25
JP6594862B2 true JP6594862B2 (ja) 2019-10-23

Family

ID=52103891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016520243A Active JP6594862B2 (ja) 2013-06-19 2014-06-18 五員複素環縮合ピリジン系化合物、並びにその調製方法および用途

Country Status (14)

Country Link
US (1) US9988381B2 (ru)
EP (1) EP3012259B1 (ru)
JP (1) JP6594862B2 (ru)
KR (1) KR102289681B1 (ru)
CN (1) CN104230922B (ru)
AU (1) AU2014284013B2 (ru)
BR (1) BR112015030953B1 (ru)
CA (1) CA2908824C (ru)
DK (1) DK3012259T3 (ru)
ES (1) ES2802101T3 (ru)
PT (1) PT3012259T (ru)
RU (1) RU2668074C2 (ru)
SG (1) SG11201509511QA (ru)
WO (1) WO2014201857A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
IL312480A (en) 2021-11-05 2024-06-01 Haihe Biopharma Co Ltd A solid dispersion, the method of preparation therefor, and a solid formulation containing the same
WO2023078408A1 (zh) * 2021-11-05 2023-05-11 上海海和药物研究开发股份有限公司 含met受体酪氨酸激酶抑制剂的药物组合及应用
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
AU2004213375A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
US7468376B2 (en) * 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
US7696229B2 (en) * 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
WO2009033084A1 (en) * 2007-09-06 2009-03-12 Array Biopharma Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors
RS58508B1 (sr) 2008-11-14 2019-04-30 Merial Inc Enantiomerno obogaćena paraziticidalna jedinjenja ariloazol-2-il cijanoetilamino
KR101023580B1 (ko) 2010-07-15 2011-03-21 전병수 승강기 와이어로프 장력 자동 균등화 장치
NZ609527A (en) 2010-10-29 2014-03-28 Pfizer N1/n2-lactam acetyl-coa carboxylase inhibitors
CN104812393A (zh) * 2012-05-08 2015-07-29 默沙东公司 用于抑制RORγ活性和治疗疾病的四氢萘啶和相关双环化合物
US20140303121A1 (en) * 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SI2970265T1 (sl) * 2013-03-15 2018-10-30 Plexxikon Inc. Heterociklične spojine in njihova uporaba
TN2016000270A1 (en) * 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.

Also Published As

Publication number Publication date
RU2668074C2 (ru) 2018-09-26
US20160137640A1 (en) 2016-05-19
AU2014284013B2 (en) 2018-04-05
EP3012259B1 (en) 2020-06-03
CA2908824C (en) 2021-05-25
KR20160032003A (ko) 2016-03-23
JP2016521757A (ja) 2016-07-25
EP3012259A4 (en) 2016-11-23
CN104230922B (zh) 2016-12-28
DK3012259T3 (da) 2020-06-22
WO2014201857A1 (zh) 2014-12-24
CA2908824A1 (en) 2014-12-24
ES2802101T3 (es) 2021-01-15
SG11201509511QA (en) 2016-01-28
BR112015030953A8 (pt) 2018-01-23
BR112015030953B1 (pt) 2022-03-29
CN104230922A (zh) 2014-12-24
RU2016101983A (ru) 2017-07-24
PT3012259T (pt) 2020-07-03
EP3012259A1 (en) 2016-04-27
AU2014284013A1 (en) 2016-02-11
KR102289681B1 (ko) 2021-08-17
US9988381B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
AU2021245150B2 (en) KRAS G12C inhibitors and methods of using the same
TWI725266B (zh) Fgfr4抑制劑、其製備方法與藥學上的應用
JP6267806B2 (ja) ２，４−二置換ベンゼン−１，５−ジアミン誘導体およびその使用ならびにそれから製造される医薬組成物および薬用組成物
AU2006331912B2 (en) Triazolopyridazines as tyrosine kinase modulators
KR102007056B1 (ko) 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸
KR101726555B1 (ko) ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체
JP6564406B2 (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
AU2005289644A1 (en) Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
TWI601724B (zh) 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
JP6594862B2 (ja) 五員複素環縮合ピリジン系化合物、並びにその調製方法および用途
JP2019534323A (ja) ナフチリジン化合物、薬物組成物およびそれらの応用
WO2019141202A1 (zh) Tam家族激酶/和csf1r激酶抑制剂及其用途
CA2982862C (en) Preparation and use of kinase inhibitor
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
AU2022305807A1 (en) Pyrimidine compounds for use as map4k1 inhibitors
WO2024023330A1 (en) Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
CN112625027A (zh) 杂环衍生物及其用途

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161220

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190925

R150 Certificate of patent or registration of utility model

Ref document number: 6594862

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250